Palbociclib shows promising results in patients with hormone receptor-positive metast

[News]

The drug palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, significantly improved progression-free survival when administered as a first-line treatment in patients with hormone receptor-positive, metastatic breast cancer, according to phase II results of the study PALOMA-1, presented here at the AACR Annual Meeting 2014, April 5-9.

More... (http://www.medicalnewstoday.com/releases/275168.php)